Comparable stake leader
Nadav Kidron
SEC ownership of ORAMED PHARMACEUTICALS INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001176309.
Disclosed value leader
MERCER GLOBAL ADVISORS INC /ADV
Comparable rows
50/50
Latest evidence
01 Jul 2026
- Public ticker
- ORMP on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Nadav Kidron
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Nadav Kidron
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001176309
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ORAMED PHARMACEUTICALS INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nadav Kidron
Disclosed value leader
MERCER GLOBAL ADVISORS IN...
Comparable rows
50/50
Latest evidence
01 Jul 2026
3/4/5
13D/G
13F
Lead comparable stake: 7.6%
13D/G row: Nadav Kidron
Showing 1-8 of 50 holder rows.
Quick read
Nadav Kidron leads the comparable SEC ownership view at 7.6%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nadav Kidron's linked filing trail.
Comparable ownership
Top 5
Nadav Kidron
7.6%
Aquamarine Financial (Cayman) Ltd
6%
BML Investment Partners, L.P.
2.5%
Benjamin Shapiro
4.9%
Miriam Kidron
2.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nadav Kidron |
3/4/5
13D/G
President and CEO, Director
|
7.6%
from 13D/G
|
$10,112,492
3,548,243 shares
|
— | 30 Mar 2026 |
| Aquamarine Financial (Cayman) Ltd |
13F
13D/G
Company
|
6%
from 13D/G
|
$12,083,562
2,512,175 shares
|
— | 30 Jun 2026 |
| BML Investment Partners, L.P. |
13D/G
Leonard Braden Michael
|
2.5%
|
$4,094,813
1,026,269 shares
|
-$9,022,435 | 26 Jun 2026 |
| Benjamin Shapiro |
3/4/5
Director
|
4.9%
|
$6,150,588
2,023,220 shares
|
— | 31 Dec 2025 |
| Miriam Kidron |
3/4/5
Chief Scientific Officer, Director
|
2.7%
|
$3,229,443
1,133,138 shares
|
— | 30 Mar 2026 |
| Avraham Gabay |
3/4/5
Chief Financial Officer
|
1.6%
|
$3,028,742
671,785 shares
|
-$330,744 | 01 Jul 2026 |
| Arie Mayer |
3/4/5
Director
|
0.4%
|
$510,747
168,009 shares
|
— | 31 Dec 2025 |
| Leonard Sank |
3/4/5
Director
|
0.32%
|
$301,349
134,531 shares
|
— | 05 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$942,175.
Buys
$0
Insiders: 0
Sells
$942,175
Insiders: 2
Net
-$942,175
Shares: -210,360
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 210,360
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 210,360 | $0 | $942,175 | -$942,175 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to ORAMED PHARMACEUTICALS INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Nadav Kidron
Net 12M change
-$942,175
Latest report
01 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Nadav Kidron | President and CEO, Director | $10,112,492 | Mixed | 30 Mar 2026 | ||
| Benjamin Shapiro | Director | $6,150,588 | Mixed | 31 Dec 2025 | ||
| Joshua Hexter | Coo & Cbo | $3,649,505 | -$611,431 | -14% | Mixed | 01 Jul 2026 |
| Miriam Kidron | Chief Scientific Officer, Director | $3,229,443 | Mixed | 30 Mar 2026 | ||
| Avraham Gabay | Chief Financial Officer | $3,028,742 | -$330,744 | -9.8% | Filing P/S | 01 Jul 2026 |
| David Silberman | Chief Financial Officer | $809,965 | Mixed | 04 Jan 2024 | ||
| Arie Mayer | Director | $510,747 | Mixed | 31 Dec 2025 | ||
| Daniel Aghion | Director | $344,860 | Mixed | 31 Dec 2025 | ||
| Yadin Rozov | Director | $343,257 | Mixed | 04 Jan 2024 | ||
| Netanel Derovan | Chief Legal Officer | $330,395 | Mixed | 26 May 2023 | ||
| Yehuda Reznick | Director | $319,747 | Mixed | 31 Dec 2025 | ||
| Leonard Sank | Director | $301,349 | Mixed | 05 Jun 2025 | ||
| Michael Rabinowitz | Chief Commercial Officer | $278,776 | Mixed | 03 Jan 2023 | ||
| Michael Rabinowitz | Chief Commercial Officer | $241,924 | Mixed | 03 Jan 2022 | ||
| Kevin L. Rakin | Director | $103,121 | Mixed | 21 Mar 2022 | ||
| Aviad Friedman | Director | Mixed | 03 Jan 2022 |
Recent insider transactions for ORAMED PHARMACEUTICALS INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Joshua Hexter | ORMP | Common Stock | Options Exercise | 4.89% | 50,000 | 1,073,384 | 02 Jul 2026 | Direct | ||
| Joshua Hexter | ORMP | Stock option (right to buy) | Options Exercise | -50% | -50,000 | 50,000 | 02 Jul 2026 | Direct | ||
| Joshua Hexter | ORMP | Common Stock | Sale | -11.8% | $611,431 | $4.46 | -137,000 | 1,023,384 | 01 Jul 2026 | Direct |
| Avraham Gabay | ORMP | Common Stock | Sale | -9.85% | $330,744 | $4.51 | -73,360 | 671,785 | 01 Jul 2026 | Direct |
| Nadav Kidron | ORMP | Common Stock | Tax liability | -1.29% | -44,818 | 3,422,243 | 30 Mar 2026 | Direct | ||
| Miriam Kidron | ORMP | Common Stock | Tax liability | -27.7% | -435,084 | 1,133,138 | 30 Mar 2026 | Direct | ||
| Miriam Kidron | ORMP | Common Stock | Award | 8.25% | 119,558 | 1,568,222 | 17 Mar 2026 | Direct | ||
| Nadav Kidron | ORMP | Common Stock | Award | 5.13% | 167,005 | 3,422,243 | 17 Mar 2026 | Direct | ||
| Joshua Hexter | ORMP | Common Stock | Award | 9.01% | 95,889 | 1,160,384 | 17 Mar 2026 | Direct | ||
| Avraham Gabay | ORMP | Common Stock | Award | 14.8% | 95,889 | 745,145 | 17 Mar 2026 | Direct | ||
| Nadav Kidron | ORMP | Common Stock | Gift | -2.98% | -100,000 | 3,255,238 | 12 Mar 2026 | Direct | ||
| Nadav Kidron | ORMP | Common Stock | Options Exercise | 3.36% | 109,000 | 3,355,238 | 22 Jan 2026 | Direct | ||
| Nadav Kidron | ORMP | Performance Stock Units | Options Exercise | -100% | -109,000 | 0 | 22 Jan 2026 | Direct | ||
| Miriam Kidron | ORMP | Common Stock | Options Exercise | 1.33% | 19,000 | 1,448,664 | 22 Jan 2026 | Direct | ||
| Miriam Kidron | ORMP | Performance Stock Units | Options Exercise | -100% | -19,000 | 0 | 22 Jan 2026 | Direct | ||
| Joshua Hexter | ORMP | Common Stock | Options Exercise | 1.82% | 19,000 | 1,064,495 | 22 Jan 2026 | Direct | ||
| Joshua Hexter | ORMP | Performance Stock Units | Options Exercise | -100% | -19,000 | 0 | 22 Jan 2026 | Direct | ||
| Avraham Gabay | ORMP | Common Stock | Options Exercise | 3.01% | 19,000 | 649,256 | 22 Jan 2026 | Direct | ||
| Avraham Gabay | ORMP | Performance Stock Units | Options Exercise | -100% | -19,000 | 0 | 22 Jan 2026 | Direct | ||
| Miriam Kidron | ORMP | Common Stock | Gift | -6.03% | -86,166 | 1,343,498 | 14 Jan 2026 | Direct | ||
| Yehuda Reznick | ORMP | Common Stock | Award | 52.6% | 36,250 | 105,180 | 31 Dec 2025 | Direct | ||
| Nadav Kidron | ORMP | Common Stock | Award | 20.8% | 559,640 | 3,246,238 | 31 Dec 2025 | Direct | ||
| Nadav Kidron | ORMP | Performance Stock Units | Award | 109,000 | 109,000 | 31 Dec 2025 | Direct | |||
| Miriam Kidron | ORMP | Common Stock | Award | 19.8% | 236,331 | 1,429,664 | 31 Dec 2025 | Direct | ||
| Miriam Kidron | ORMP | Performance Stock Units | Award | 19,000 | 19,000 | 31 Dec 2025 | Direct | |||
| Joshua Hexter | ORMP | Common Stock | Award | 25.5% | 212,328 | 1,045,495 | 31 Dec 2025 | Direct | ||
| Joshua Hexter | ORMP | Performance Stock Units | Award | 19,000 | 19,000 | 31 Dec 2025 | Direct | |||
| Benjamin Shapiro | ORMP | Common Stock | Award | 37.3% | 33,500 | 123,220 | 31 Dec 2025 | Direct | ||
| Arie Mayer | ORMP | Common Stock | Award | 26.2% | 34,900 | 168,009 | 31 Dec 2025 | Direct | ||
| Daniel Aghion | ORMP | Common Stock | Award | 47% | 36,250 | 113,441 | 31 Dec 2025 | Direct | ||
| Avraham Gabay | ORMP | Common Stock | Award | 45.2% | 196,216 | 630,256 | 31 Dec 2025 | Direct | ||
| Avraham Gabay | ORMP | Performance Stock Units | Award | 19,000 | 19,000 | 31 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.